title: [Advances in clinical research on rtA181 mutation in hepatitis B virus].
abstract: Nowadays, nucleos(t)ide analogues (NAs) are important drugs for the treatment of chronic hepatitis B and can suppress the virus through inhibiting the activity of hepatitis B virus (HBV) polymerase. However, rtA181 mutation in HBV can reduce the sensitivity of HBV to various NAs, which brings new challenges to antiviral therapy. This article briefly introduces the research advances in the clinical detection rate of rtA181 mutation and its influence on therapeutic effect and prognosis.
authors.affiliation: Department of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
authors.forename: X L
authors.initials: XL
authors.lastname: Gong
authors.affiliation: BGI-Shenzhen, Shenzhen 518085, China.
authors.forename: R
authors.initials: R
authors.lastname: Liu
authors.affiliation: The Third Hospital of Shenzhen, Shenzhen 518112, China.
authors.forename: Y X
authors.initials: YX
authors.lastname: Liu
authors.affiliation: Department of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D017354:Point Mutation; D011379:Prognosis
chemical_list: D000998:Antiviral Agents
keywords: Hepatitis B virus; Mutation; Rescue therapy